1. Nonalcoholic steatohepatitis: Mayo Clinic experience with an hitherto unnamed disease;Ludwig;Mayo Clin Proc,1980
2. Matsubayashi T. Drug development for nonalcoholic steatohepatitis (NASH) with fibrosis: a regulatory perspective. In: Available at: https://sbiaevents.com/files2/NASH-Webinar-January-2021.pdf.; 2021. p. Accessed March 28, 2024.
3. Changing epidemiology, global trends and implications for outcomes of NAFLD;Wong;J Hepatol,2023
4. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review;Younossi;Hepatology,2023
5. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2018